

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Pharmaron Beijing Co., Ltd.**

**康龍化成(北京)新藥技術股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3759)**

**ANNOUNCEMENT ON (I) RESIGNATION OF INDEPENDENT  
NON-EXECUTIVE DIRECTOR;**

**(II) PROPOSED CHANGE IN COMPOSITION OF THE BOARD;**

**(III) PROPOSED AMENDMENT TO THE INDEPENDENT  
NON-EXECUTIVE DIRECTORS WORKING POLICY;**

**(IV) PROPOSED CANCELLATION OF REPURCHASED  
A SHARES AND REDUCTION OF REGISTERED CAPITAL;**

**AND**

**(V) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

**I. RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “**Company**”) announces that Mr. Zhou Qilin (“**Mr. Zhou**”), an independent non-executive Director (an “**INED**”) of the Company, has tendered his resignation as an independent non-executive Director with effect from November 27, 2024 in compliance with the relevant rules on the part-time management of members of the Chinese Academy of Engineering. Mr. Zhou confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), or the shareholders of the Company.

Following his resignation, Mr. Zhou ceased to be an INED of the Company and a member of the strategy committee of the Board.

Mr. Zhou has been diligent, independent and impartial during his tenure of directorship, and has been committed to improving the standard operation and healthy development of the Company, and has provided many valuable suggestions for the sustainable development of the Company by virtue of his accumulated rich experience in scientific research. The Board would like to express its heartfelt gratitude to Mr. Zhou for his contribution to the Company and the Board during his tenure of directorship.

**II. PROPOSED CHANGE IN COMPOSITION OF THE BOARD**

The Board is pleased to announce that it was resolved at the 11th meeting of the third session of the Board on November 27, 2024 (the “**Board Meeting**”) that, subject to approval at the upcoming second extraordinary general meeting of 2024 (the “**EGM**”), the composition of the Board will be adjusted and shall consist of eight Directors in total, consisting of three executive Directors, two non-executive Directors and three INEDs (the “**Proposed Change in Board Composition**”).

### **III. PROPOSED AMENDMENT TO THE INDEPENDENT NON-EXECUTIVE DIRECTORS WORKING POLICY**

The Board announces that it was resolved at the Board Meeting that, subject to approval at the upcoming EGM, to amend the Independent Non-Executive Directors Working Policy of the Company (the “**INED Working Policy**”) in accordance with the articles of association of the Company (the “**Articles of Association**”) and the latest requirements to reflect the Proposed Change in Board Composition.

### **IV. PROPOSED CANCELLATION OF REPURCHASED A SHARES AND REDUCTION OF REGISTERED CAPITAL**

References are made to the announcements of the Company dated April 25, 2024 and July 26, 2024 (collectively, the “**Announcements**”) in relation to, among other things, the repurchase of A shares of the Company (the “**A Shares**”) through centralized price bidding by the Company and the results of the repurchase of A Shares.

The Board announces that, subject to approval at the upcoming EGM and relevant class meetings of the Company, the Company intends to cancel 9,608,288 A Shares repurchased by the Company as detailed in the Announcements (the “**Proposed Cancellation of Repurchased A Shares and Registered Capital Reduction**”). Upon completion of the Proposed Cancellation of Repurchased A Shares and Registered Capital Reduction, it is expected that the total issued share capital of the Company will reduce from 1,787,394,297 shares (consisting of 1,485,857,172 A Shares and 301,537,125 H Shares) to 1,777,786,009 shares (consisting of 1,476,248,884 A Shares and 301,537,125 H Shares), and the total registered share capital will reduce from RMB1,787,394,297 to RMB1,777,786,009.

### **V. PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

The Board announces that it was resolved at the Board Meeting that, subject to approval at the upcoming EGM of the Company, the Articles of Association will be revised to reflect the Proposed Change in Board Composition and Proposed Cancellation of Repurchased A Shares and Registered Capital Reduction.

### **VI. THE EGM, H SHARE CLASS MEETING AND CLOSURE OF REGISTER OF MEMBERS**

A circular containing, amongst others, additional information regarding (i) the Proposed Change in Board Composition; (ii) the proposed amendment of the INED Working Policy; (iii) the Proposed Cancellation of Repurchase A Shares and Registered Capital Reduction; (iv) the proposed amendments of the Articles of Association; and (v) details of the upcoming EGM and the second H Share class meeting of 2024 (the “**H Share Class Meeting**”) will be published for the information of the H Shareholders in due course.

The Board hereby announces that, for determining the list of shareholders of H Shares who are entitled to attend and vote at the EGM and the H Share Class Meeting which is scheduled to be held at 2:30 p.m. on December 18, 2024, the register of members of the H Shares will be closed from Friday, December 13, 2024 to Wednesday, December 18, 2024 (both days inclusive), during which no transfer of H Shares will be registered. The shareholders of H Shares whose names appear on the register of members of the Company on Friday, December 13, 2024 will be entitled to attend and vote at the EGM and the H Share Class Meeting.

In order to be eligible for attending and voting at the EGM and the H Share Class Meeting, all transfers of H Shares accompanied by the relevant share certificates must be lodged with the Company's H share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on Thursday, December 12, 2024.

By order of the Board  
**Pharmaron Beijing Co., Ltd.**  
**Dr. Lou Boliang**  
*Chairman*

Beijing, the PRC  
November 27, 2024

*As at the date of this announcement, the Board comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Hu Baifeng and Mr. Li Jiaqing as non-executive Directors; Ms. Li Lihua, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.*